{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:56:42Z","timestamp":1791190602705,"version":"4.1.0"},"reference-count":9,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"abstract":"<jats:p>Introduction: The combination of venetoclax (VEN) and a hypomethylation agent (HMA) was introduced for the treatment of acute myeloid leukemia (AML) because it achieved significantly better results compared to HMA monotherapy (HMA-mono). Since introducing a new method into standard care is always a challenge, the goal of this retrospective analysis was to examine AML treatment before and after the approval of HMA-VEN at an office-based center for hematology and oncology (MVZ). Methods: All newly diagnosed AML patients between January 2017 and April 2025 were fully documented and analyzed in an Excel database. Results: In total, 65 patients were included; of these, 22 (mean age 59.6 years (y) (SD 15.35)), were admitted to the university hospital. Of the remaining 43 patients (mean age 79.4 y (SD 5.86)), 1 was treated with cytosine arabinoside (ARA-C), 7 with best supportive care (BSC), 15 with HMA-mono, and 20 with the HMA-VEN. The mean overall survival (OS) of the BSC, HMA-mono, and HMA-VEN was 19.6 (SD 15.04), 25.9 (SD 28.87), and 51.7 (SD 49.09) weeks, respectively. In the HMA-VEN cohort there was no tumor lysis syndrome, 11 (55%) patients had an infection, and fourteen (70%) required hospitalization during the first two treatment cycles. Conclusion: HMA-VEN has been successfully integrated into standard care, which is primarily provided on an outpatient basis, and exhibits a safety and toxicity profile comparable to that of inpatient treatment. HMA-VEN is well tolerated subjectively in the subgroup of older patients and, in a historical comparison with the previous standard therapy, HMA-mono, or BSC, results in significantly longer overall survival without leading to an increase in complications or premature deaths.<\/jats:p>","DOI":"10.1159\/ort\/aecag004","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:51:17Z","timestamp":1787226677000},"page":"1-1","source":"Crossref","is-referenced-by-count":0,"title":["The Introduction of Hypomethylation Agents and Venetoclax into Standard Care for Older Patients with Acute Myeloid Leukemia: A Retrospective Real-World Analysis of Feasibility, Safety, and Effectiveness from an Outpatient Hematology Center"],"prefix":"10.1159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-3109","authenticated-orcid":false,"given":"H.Tilman","family":"Steinmetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Phillip","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101503"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.303"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025409"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510223"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01000-2"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5232"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/ort\/aecag004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:47:49Z","timestamp":1791190069000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/ort\/aecag004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":9,"URL":"https:\/\/doi.org\/10.1159\/ort\/aecag004","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.33306150","asserted-by":"subject"}]},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}